Hepatitis Treatment News : Poll: 75% of Primary Care Docs Unaware of New Hep C Meds
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis Treatment News » June 2014


emailprint

June 25, 2014

Poll: 75% of Primary Care Docs Unaware of New Hep C Meds

About three-quarters of primary care physicians (PCPs) are unfamiliar with the new generation of hepatitis C virus (HCV) drugs, according to a survey conducted by Decision Resources Group. The private organization surveyed 100 primary care physicians, 44 gastroenterologists and seven hepatologists for a report on how new hep C medications will “impact the role of PCPs in treating HCV patients.”

About 75 percent of the polled PCPs did not know that Janssen’s Olysio (simeprevir) and Gilead Sciences’ Sovaldi (sofosbuvir) received U.S. Food and Drug Administration (FDA) approval in 2013. Less than one in three of the physicians were even familiar with the first-generation hep C protease inhibitors, Incivek (telaprevir) and Victrelis (boceprevir), despite the fact that they have been on the market for almost three years.

More than half of the specialists polled said they were comfortable with the notion of having PCPs prescribe all-oral, interferon-free hep C drug regimens to patients with a minimal amount of liver damage. However, about one-third of the PCPs polled said they anticipated always referring such patients to a specialist.

To read the press release, click here.

Search: Hepatitis C, Gilead Sciences, Sovaldi, sofosbuvir, Janssen, Olyiso, simeprevir, primary care physicians.


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Should Medicaid limit access to new hep C drugs?
Yes
No


Survey
Hepatitis C Reader Survey
HEP ON TWITTER
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.